This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy
by Zacks Equity Research
Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
by Zacks Equity Research
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Nektar's Pain Drug Gets Adverse Advisory Committee Decision
by Zacks Equity Research
Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.
Snap Up These 5 Stocks With High Earnings Yield
by Zacks Equity Research
Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed-income securities.
3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio
by Benjamin Rains
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
Top Ranked Income Stocks to Buy for January 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 15th.
Top Ranked Income Stocks to Buy for January 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 14th.
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $66.15, marking a +1.41% move from the previous day.
The Extreme Risks of Trading Your Own Retirement Assets - January 13, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Retirees Should Know These 3 Facts About Required Minimum Distributions - January 13, 2020
by Zacks Equity Research
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration
by Zacks Equity Research
Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), McDonald's (MCD) and Bristol-Myers Squibb (BMY).
3 Reasons Growth Investors Will Love Bristol-Myers (BMY)
by Zacks Equity Research
Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.
Zacks.com featured highlights include: Helen of Troy, Penn National Gaming, Arcos Dorados, Insight Enterprises and Bristol-Myers Squibb
by Zacks Equity Research
Zacks.com featured highlights include: Helen of Troy, Penn National Gaming, Arcos Dorados, Insight Enterprises and Bristol-Myers Squibb
Easy Investing Secrets to an Early Retirement - January 08, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Can Bristol-Myers (BMY) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer/Merck KGaA's Bavencio Positive in Bladder Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA's Bavencio meets the primary goal in a late-stage study evaluating it as a first-line maintenance therapy for metastatic urothelial carcinoma, a form of bladder cancer.
5 High-Flying Stocks Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $62.98, marking a +0.32% move from the previous day.
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
by Zacks Equity Research
Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.
AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA
by Zacks Equity Research
AstraZeneca (AZN) gets the FDA's priority review status for its sNDA seeking label expansion of Farxiga for patients with heart failure with reduced ejection fraction.
Leap Therapeutics Surges on License Agreement With BieGene
by Zacks Equity Research
Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.